4
Changes in Ownership
CytomX Therapeutics, Inc. Filed Acc 0001140361-17-021016
Chief Financial Officer acquired 19,967 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Goeltz II Robert C. · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2017-05-12 | Exercise or conversion : show line 1 in the form | +9,980 | $4.47 | $44,639 | 22,769 | D |
| 2017-05-12 | Exercise or conversion : show line 2 in the form | +9,987 | $6.61 | $66,061 | 32,756 | D |
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2017-05-12 | Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) | −9,980 | 204,678 | D |
| 2017-05-12 | Exercise or conversion : show line 4 in the form Stock Option (Right to Buy) | −9,987 | 85,891 | D |
Loading xslF345X03/doc1.xml…